
News|Articles|November 1, 2006
Pipeline Preview (November 2006)
Lisdexamfetamine (NRP104, Shire/New River Pharmaceuticals) for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
2
Jaypirca shows promise as a frontline treatment for CLL/SLL patients | ASH 2025
3
Gene therapy in the real world: High priced, a long process and still relatively few patients | ASH 2025
4
Venclexta combination improves survival and lowers hospital stays for AML patients | ASH 2025
5





















































